[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 17, Issue 4 (Winter 2020) ::
Sci J Iran Blood Transfus Organ 2020, 17(4): 322-335 Back to browse issues page
Identification, Prevention and management of platelet refractoriness
Saeideh Milani Dr. , Fatemeh Yari Dr.
Keywords: Key words: Platelet Transfusion, Immunoglobulin, Antibodies
      |   Abstract (HTML)  (400 Views)
Type of Study: Review Article | Subject: Imunohematology
Published: 2020/12/30
Full-Text:   (97 Views)
    References:
  1. Shiri R, Yari F, Ahmadinejad M, Vaeli S, Tabatabaei MR. The caspase-3 inhibitor (peptide Z-DEVD-FMK) affects the survival and function of platelets in platelet concentrate during storage. Blood Res 2014; 49(1): 49-53.
  2. Ahmadzadeh N, Yari F, Amirizadeh N, Khorramizadeh MR. Production and characterization of liquid-stored and lyophilized reconstituted human infusible platelet membranes.  Int J Lab Hematol. 2011; 33(6): 586-92.
  3.  Rebulla P. A mini-review on platelet refractoriness. Haematologica 2005; 90(2): 247-53.
  4. Kerkhoffs JL, Eikenboom JC, van de Watering LM, van Wordragen-Vlaswinkel RJ, Wijermans PW, Brand A. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion 2008; 48(9): 1959-65.
  5. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008; 142(3): 348-60.
  6. Davis KB, Slichter SJ, Corash L. Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion 1999; 39(6): 586-92.
  7. Forest SK, Hod EA. Management of the platelet refractory patient. Hematol Oncol Clin North Am 2016; 30(3): 665-77.
  8. Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness–practical approaches and ongoing dilemmas in patient management. Br J Haematol 2015; 171(3): 297-305.
  9. Schmidt AE, Refaai MA, Coppage M. HLA-Mediated Platelet Refractoriness: An ACLPS Critical Review. Am J Clin Pathol 2019; 151(4): 353-63.
  10. Wiita AP, Nambiar A. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME). Transfusion 2012; 52(10): 2146-54.
  11. Fontão-Wendel R, Silva LC, Saviolo CB, Primavera B, Wendel S. Incidence of transfusion-induced platelet-reactive antibodies evaluated by specific assays for the detection of human leucocyte antigen and human platelet antigen antibodies. Vox Sang 2007; 93(3): 241-9.
  12. Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek FWG, Jansen AJG. Emerging concepts in immune thrombocytopenia. Front Immunol 2018; 9: 880.
  13. Sullivan HC, Gebel HM, Bray RA. Understanding solid-phase HLA antibody assays and the value of MFI. Hum Immunol 2017; 78(7-8): 471-80.
  14. Lachmann N, Todorova K, Schulze H, Schönemann C. Luminex® and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion. Transfus Med Hemother 2013; 40(3): 182-9.
  15. Schnaidt M. Luminex single antigen bead testing: adding EDTA to serum abolishes the hook effect. Clin Lab 2011; 57(7-8): S8.
  16. Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D. HLA antibody specification using single-antigen beads--a technical solution for the prozone effect. Transplantation 2011; 92(5): 510-5.
  17. El-Awar N, Jucaud V, Nguyen A. HLA epitopes: the targets of monoclonal and alloantibodies defined. J Immunol Res 2017; 2017: 3406230.
  18. Morales-Buenrostro LE, Terasaki PI, Marino-Vázquez LA, Lee JH, El-Awar N, Alberú J. “Natural” human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86(8): 1111-5.
  19. Katalinić N, Starčević A, Mavrinac M, Balen S. Complement-dependent cytotoxicity and Luminex technology for human leucocyte antigen antibody detection in kidney transplant candidates exposed to different sensitizing events. Clin Kidney J 2017; 10(6): 852-8.
  20. Chowdhry M, Makroo RN, Thakur Y, Sharma V, Singh M, Kumar M.  The good, the bad, and the ugly of luminex donor-specific crossmatch. HLA 2018; 91(6): 501-6.
  21. Mostakhdemin  Hosseini  M,  Samiee  S, Shaiegan M, Mohammadi S, Jalaiekhoo H, Tabatabiepanah P, et al. Evaluation of platelet antigens and antibodies in patients with platelet refractoriness. Sci J Iran Blood Transfus Organ 2019; 16(2): 91-102. [Article in Farsi]
  22. Weinstock C, Schnaidt M. Human Leucocyte Antigen Sensitisation and Its Impact on Transfusion Practice. Transfus Med Hemother 2019; 46(5): 356-69.
  23. Altermann WW, Seliger B, Sel S, Wendt D, Schlaf G.  Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA-based HLA crossmatch procedure. Histol Histopathol 2006; 21(10): 1115-24.
  24. Wu YY, Csako G. Rapid and/or high-throughput genotyping for human red blood cell, platelet and leukocyte antigens, and forensic applications. Clin Chim Acta 2006; 363(1-2): 165-76. 
  25. Abbas MM. DNA yield from buccal swabs and its utilization in HLA typing using luminex SSO bead technology. Human Immunol 2004; 9(65): S81.
  26. Chang Y. Is HLA Matching By SBT A Necessity For BMT? Biol Blood Marrow Transplant 2010; 16(2): S219.
  27. Skogen B, Husebekk A. A strategy for platelet transfusion in patients with alloantibodies to platelets. Transfus Alt Transfus Med 2006; 8(2): 114-20.
  28. Porcelijn L, Huiskes E, de Haas M. Progress and development of platelet antibody detection. Transfus Apher Sci 2020; 59(1): 102705.
  29. Metzner K, Bauer J, Ponzi H, Ujcich A, Curtis BR. Detection and identification of platelet antibodies using a sensitive multiplex assay system-platelet antibody bead array. Transfusion 2017; 57(7): 1724-33. 
  30. Brown CJ, Navarrete CV. Clinical relevance of the HLA system in blood transfusion. Vox Sang 2011; 101(2): 93-105. 
  31. Yari F, Sobhani M, Vaziri MZ, Bagheri N, Sabaghi F, Talebian A. Association of aplastic anaemia and Fanconi's disease with HLA-DRB1 alleles. Int J Immunogenet 2008; 35(6): 453-6.
  32. Novotný VM, Doxiadis II, Brand A. The reduction of HLA class I expression on platelets: a potential approach in the management of HLA-alloimmunized refractory patients. Transfus Med Rev 1999; 13(2): 95-105. 
  33. Bub CB, Torres MA, Moraes ME, Hamerschlak N, Kutner JM. Determination of an unrelated donor pool size for human leukocyte antigen-matched platelets in Brazil. Rev Bras Hematol Hemoter 2016; 38(1): 1-6.
  34. Simon TL, McCullough J, Snyder EL, Solheim BG. Rossi's principles of transfusion medicine. USA: John Wiley & Sons; 2016; 38(1):1-6.
  35. Chavan P, Chauhan B, Joshi  A, Ojha Sh, Bhat V. Differential diagnosis of thrombocytopenia in hematopoietic stem cell transplant patients. J Hematol Thrombo Dis 2014; 2(6): 1000168.
  36. Holland L. Role of ABO and Rh type in platelet transfusion. Lab Med 2006; 37(12): 758-60.
  37. Pandey S, Rosenbaum E, Cottler-Fox M, Harville TO. Percent cPRA (Calculated Panel Reactive Antibody) Value   Predicts   Percent   of       Positive   Platelet Crossmatches. Ann Clin Lab Sci 2017; 47(3): 315-8.
  38. Nambiar A, Duquesnoy RJ, Adams S, Zhao Y, Oblitas J, Leitman S, et al. HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood 2006; 107(4): 1680-7. 
  39. Salama OS, Aladl DA, El Ghannam DM, Elderiny WE. Evaluation of platelet cross-matching in the management of patients refractory to platelet transfusions. Blood Transfus 2014; 12(2): 187-94.
  40. Vassallo RR, Fung M, Rebulla P, Duquesnoy R, Saw CL, Slichter SJ, et al. Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion 2014; 54(4): 1180-91.
  41. Kopko PM, Warner P, Kresie L, Pancoska C. Methods for the selection of platelet products for alloimmune-refractory patients. Transfusion 2015; 55(2): 235-44.
  42. Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, et al. Selecting donors of platelets for refractory patientson the basis of HLA antibody specificity. Transfusion 2000; 40(12): 1446-56.
  43. Pai SC, Lo SC, Lin Tsai SJ, Chang JS, Lin DT, Lin KS,  et al. Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases. Transfusion 2010; 50(11): 2318-27.
  44. Duquesnoy RJ. Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support? Transfusion 2008; 48(2): 221-7.
  45. Brooks EG, MacPherson BR, Fung MK. Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions. Transfusion 2008; 48(10): 2159-66.
  46. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105(10): 4106-14.
  47. Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer 2006; 107(1): 136-40.
  48. Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, et al. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer 2013; 119(21): 3784-7.
  49. Colman RW, Alexander W, Goldhaber SZ, Marder VJ, George JN. Hemostasis and thrombosis: basic principles and clinical practice. 5th ed. USA: Lippincott Williams & Wilkins; 2007; 104(5): 1317.
  50. Garraud O, Cognasse F, Moncharmont P. Immunological Features in the Process of Blood Platelet-Induced Alloimmunisation, with a Focus on Platelet Component Transfusion. Diseases 2019; 7(1): 7.
  51. Aloui C, Chakroun T, Prigent A, Jemni-Yacoub S, Cognasse F, Laradi S, et al. Leucocyte cytokines dominate platelet cytokines overtime in non-leucoreduced platelet components. Blood Transfus 2018; 16(1): 63-72.
  52. Ancy Susan J. Prevalence and Characterisation of Platelet Alloantibodies in Hematology Patients Refractory to Platelet Transfusions: Experience from a Tertiary Care Centre in South India. Christian Medical College, Vellore; 2016.
  53. Sharma RR, Marwaha N. Leukoreduced blood components: Advantages and strategies for its implementation in developing countries. Asian J Transfus Sci 2010; 4(1): 3-8.
  54. Revelli N, Villa MA, Olivero B, Bresciani S, Flores M, Marini M, et al. A real-life evaluation of two platelet cross-matching programmes for the treatment of patients refractory to platelet transfusions. Vox Sang 2019; 114(1): 73-8.
  55. Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY,  et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103(1): 333-9.
  56. Lehner B, Eichelberger B, Jungbauer C, Panzer S. The Blood Group A Genotype Determines the Level of Expression of the Blood Group A on Platelets But Not the Anti-B Isotiter. Transfus Med Hemother 2015; 42(6): 366-71.
  57. Rajadhyaksha BS, Desai DP, Navkudkar AA. Platelet refractoriness. Global Journal of Transfusion Medicine 2019; 4(2): 140-7.
  58. Lozano M, Heddle N, Williamson LM, Wang G, AuBuchon JP, Dumont LJ, et al. Practices associated with ABO-incompatible platelet transfusions: a BEST Collaborative international survey. Transfusion 2010; 50(8): 1743-8.
  59. Shehata N, Tinmouth A, Naglie G, Freedman J, Wilson K. ABO-identical versus nonidentical platelet transfusion: a systematic review. Transfusion 2009; 49(11): 2442-53.
  60. Pavenski K, Warkentin TE, Shen H, Liu Y, Heddle NM. Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study. Transfusion 2010; 50(7): 1552-60.
  61. Julmy F, Ammann RA, Taleghani BM, Fontana S, Hirt A, Leibundgut K. Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs. Transfusion 2009; 49(1): 21-33.
  62. Kaufman RM. Platelet ABO matters. Transfusion 2009; 49(1): 5-7.
  63. Triulzi DJ, Assmann SF, Strauss RG, Ness PM, Hess JR, Kaufman RM, et al. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 2012; 119(23): 5553-62.
  64. Jackman RP, Deng X, Bolgiano D, Lebedeva M, Heitman JW, Busch MP, et al. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants. Blood 2013; 121(16): 3261-6.
  65. Saris A, Tomson B, Brand A, Mulder A, Claas FH, Lorinser J, et al. Platelets from donors with consistently low HLA-B8,-B12, or-B35 expression do not undergo antibody-mediated internalization. Blood 2018; 131(1): 144-52.
  66. Valsami S, Dimitroulis D, Gialeraki A, Chimonidou M, Politou M. Current trends in platelet transfusions practice: The role of ABO-RhD and human leukocyte antigen incompatibility. Asian J Transfus Sci 2015; 9(2): 117-23.
 
 
 
 
 
 
 
 


 
 
 
Sci J Iran Blood Transfus Organ 2020; 17 (4); 322-335
Review  Article
 

 

Identification, Prevention and management of platelet refractoriness
 
Milani S.1, Yari F.1
 
 
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
 
 
Abstract
Background and Objectives
Platelet refractoriness can be caused by immunological and non-immunological factors. In non-immunological cases, the source which is usually a disease, should be eliminated. In immunological cases antibodies produced against foreign platelet antigens play a significant role. The aim of this review was to investigate the strategies involved in identifying and preventing immunological platelet refractoriness .
 
Materials and Methods
This article reviews the tests used to identify platelet refractoriness for selection of compatible platelets, as well as prevention and management of the disease. This was done by using keywords; Platelet Transfusion, Platelet Refractory, Corrected Count Increment and Alloantibody and their Persian equivalents through scientific database including  Science Direct, PubMed Medline, SID, Scopus and Magiran, and finally among 100 related articles, 66  were selected.
 
Results
Since the main immunological cause of platelet refractoriness is production of anti-HLA antibodies, screening for these antibodies is very important. Cross-matching and antibody-specificity prediction can also be performed for these patients. In emergencies, plasma replacement, intravenous immunoglobulin injection, and use of certain medications and compounds could be helpful.
 
Conclusions 
Investigating the efficacy of different methods in diagnosis of platelet refractoriness and detection of compatible platelets has a great impact on prevention, treatment and better management of the disease.
 
Key words: Platelet Transfusion, Immunoglobulin, Antibodies
 
 
 
 
 
 
 
Received:  14 Jan 2020
Accepted: 14 Jun 2020
 
 

Correspondence: Milani S., PhD of Medical Biotechnology. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.
 P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 88993778; Fax: (+9821) 88993778
E-mail: s.milani@tmi.ac.ir
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Milani S, Yari F. Identification, Prevention and management of platelet refractoriness. Sci J Iran Blood Transfus Organ. 2020; 17 (4) :322-335
URL: http://bloodjournal.ir/article-1-1329-en.html


Volume 17, Issue 4 (Winter 2020) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.51 seconds with 31 queries by YEKTAWEB 4269